WILMINGTON – Startup cancer research company Prelude Therapeutics closed a public offering of 2.5 million shares on Monday, Jan. 11, as well as an additional 375,000 shares to underwriters, raising a reported $172.5 million. The ...
WILMINGTON – A few days after announcing that it would offer 1.75 million new shares on the market, startup cancer research company Prelude Therapeutics increased its offering to more than 2.2 million voting shares. The ...
WILMINGTON – The hot biotech startup Prelude Therapeutics announced Jan. 4 that it intends to offer 1.75 million shares of its common stock, according to regulatory filings. The clinical-stage precision oncology company also reported that ...
Kris Vaddi Founder and CEO, Prelude Therapeutics When Kris Vaddi and his team at Prelude Therapeutics decided to take their specialty cancer drug development company public, he never dreamed that it would turn into a ...
By Michael Fleming The extraordinarily successful initial public offering by Prelude Therapeutics (PRLD) last month made clear investors’ immense confidence in prospects for the Wilmington biopharmaceutical company. Prelude’s market capitalization quickly shot past $1 billion, ...
WILMINGTON – After weeks of waiting and behind-the-scenes negotiating, Prelude Therapeutics closed its initial public offering Thursday night at its highest targeted price point of $19 a share, resulting in $158.2 million in proceeds. Prelude, ...
WILMINGTON – Prelude Therapeutics, a private biotechnology startup company headquartered at the Delaware Innovation Space, has set its sights on a $150 million initial public offering (IPO), increasing the sale by about 50% from its ...
WILMINGTON – Fresh off Series C funding closed last month, Prelude Therapeutics, a private life sciences start-up company headquartered in Alapocas, has announced that it is pursuing an initial public offering (IPO) worth as much ...
WILMINGTON – Prelude Therapeutics, a private life sciences start-up company, announced Aug. 24 that it has closed a $50 million Series C financing round, continuing its explosive growth in only four years. The new funds ...
Over the past five years, the bioscience industry in Delaware has undergone significant changes that were both negative and positive. Earlier this decade we lost about 12% of our jobs due to business decisions by ...
Movers, shakers, difference-makers Delaware has plenty of talented people, but who is set to make the biggest impact in 2019? Delaware Business Times asked industry leaders who they thought would be the biggest names in ...
By Dan Linehan Special to Delaware Business Times It’s natural to draw parallels between Kris Vaddi’s time discovering drugs at Incyte, where he spent 14 years, and his latest startup venture, Prelude Therapeutics. But there ...
A founding scientist and previous vice president of the pharmaceutical company Incyte is growing his next venture in Delaware. The state Council on Development Finance (CDF) voted Monday to recommend a performance-based grant package for Prelude Therapeutics. ...
Kris Vaddi has spent enough time in classrooms and laboratories to understand the power of discovery. More importantly, he knows that it cannot be ...
Popular Posts
-
🔒 Pike Creek Shopping Center to get redesignJune 27, 2020 -
🔒 Exclusive: Amazon leases future mega warehouse near BearOctober 27, 2020
-
Bioscience startups need support beyond the incubator stageSeptember 16, 2019
